Epipangi-Dx: A Cell-Free Dna Methylation Fingerprint For The Early Detection Ofgastrointestinal Cancers
Tech ID: 34529 / UC Case 2021-721-0
Brief Description
A novel method for detecting, diagnosing, monitoring, and treating gastrointestinal cancers by analyzing DNA methylation levels in patient samples.
Full Description
This technology provides comprehensive methods to measure methylation levels of CpG sites in DNA samples from patients to detect and diagnose gastrointestinal cancers early. It enables monitoring of treatment efficacy and cancer risk by comparing DNA methylation levels over time. The methods cover multiple types of GI cancers including colorectal, liver, esophageal, gastric, and pancreatic cancers by assessing methylation patterns in a panel of gene regions specific to each cancer type.
Suggested uses
- Early screening tests for gastrointestinal cancers in at-risk and general populations.
- Diagnostic tools for clinical oncology to confirm GI cancer diagnoses.
- Monitoring tools to evaluate patient response to cancer therapies.
- Companion diagnostic platforms to guide personalized cancer treatment choices.
- Research assays for studying epigenetic changes in gastrointestinal cancers.
Advantages
- Enables early detection of gastrointestinal cancers through minimally invasive blood tests.
- Monitors cancer progression and treatment response via sequential methylation level assessments.
- Covers multiple GI cancer types with specific gene region methylation profiles.
- Supports personalized cancer treatment planning through precise molecular diagnostics.
- Cost-effective compared to current screening methods, suitable for population screening.
Patent Status
| Country | Type | Number | Dated | Case |
| Patent Cooperation Treaty | Reference for National Filings | WO 2023/023123 | 02/23/2023 | 2021-721 |
Patent Pending
Related Materials
Contact
- Ronnie Hanecak
- rhanecak@uci.edu
- tel: View Phone Number.
